Skip to main content
. 2018 Sep 27;36:196–208. doi: 10.1016/j.ebiom.2018.09.034

Fig. 6.

Fig. 6

Screened drugs with selective sensitivity toward the KRAS subtypes.

(a) Drugs that selectively killed CS1 or CS2.

(b–m) CS1-specific drugs that are ordered by logFC: enzastaurin, lestaurtinib, cytarabine, docetaxel, vinblastine, cisplatin, AZD7762, NU7441, olaparib, GSK429286A, tanespimycin and CCT-018159. The Wilcoxon test was used for the pairwise comparison.

(n) CS2-specific drug: QL-XII-61. The Wilcoxon test was used for the pairwise comparison.